Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia (Q37813392)

23 August 2017

1 reference

title

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia (English)

1 reference

23 August 2017

1 reference

myelodysplastic syndrome

1 reference

A. Quintás-Cardama

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21116282

4 September 2024

F. P S. Santos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21116282

4 September 2024

G. Garcia-Manero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21116282

4 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21116282

4 September 2024

publication date

30 November 2010

1 reference

full work available at URL

23 August 2017

https://www.nature.com/articles/leu2010276.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21116282

https://www.nature.com/articles/leu2010276.pdf

4 September 2024

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.276

https://www.nature.com/articles/leu2010276

4 September 2024

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.276

4 September 2024

1 reference

23 August 2017

volume

25

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

226-235

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

23 August 2017

1 reference

Progress in the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Controlling the double helix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylases: salesmen and customers in the post-translational modification market.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

The promise of retinoids to fight against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone acetylation-mediated regulation of genes in leukaemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Modulating molecular chaperone Hsp90 functions through reversible acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

A phase 2 study of vorinostat in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Isoform-selective histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

New stem cell center at Cornell

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.276

7 January 2021

https://api.crossref.org/works/10.1038/LEU.2010.276

68

90

986

E Raffoux

2005

1 reference

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

4 September 2024

https://api.crossref.org/works/10.1038/LEU.2010.276

78

1 reference

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

4 September 2024

https://api.crossref.org/works/10.1038/LEU.2010.276

79

1 reference

Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.

4 September 2024

https://api.crossref.org/works/10.1038/LEU.2010.276

80

1 reference

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

4 September 2024

https://api.crossref.org/works/10.1038/LEU.2010.276

82

1 reference

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

4 September 2024

https://api.crossref.org/works/10.1038/LEU.2010.276

85

1 reference

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

4 September 2024

https://api.crossref.org/works/10.1038/LEU.2010.276

88

1 reference

Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Haematological Tumors.

4 September 2024

https://api.crossref.org/works/10.1038/LEU.2010.276

97

1 reference

4 September 2024

Identifiers

DOI

10.1038/LEU.2010.276

1 reference

23 August 2017

1 reference